

Connecting Patients with their Amgen By Your Side PAL

The Patient Access Liaison (PAL) is a dedicated support partner who helps investigate, explain, and educate on the steps in your patient's treatment experience. They are your patient's point of contact and champion while your patient is accomplishing their treatment goals.

- Make sure the patient is aware their PAL will be calling them in the next few days to provide information on next steps and getting started on RAVICTI
- Have the patient save their PAL's contact in their phone
 - **It is important that a patient answers the PAL's call**

PAL Name: _____ **Phone Number:** _____

Please ensure that all four pages of the enrollment forms are submitted by fax to 1-877-695-8304 or emailed to UCDABYS@amgen.com. Incomplete forms may delay enrollment.

INDICATION and IMPORTANT SAFETY INFORMATION FOR RAVICTI (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID

INDICATION

RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).

LIMITATIONS OF USE

- RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels.
- The safety and efficacy of RAVICTI for the treatment of *N*-acetylglutamate synthase (NAGS) deficiency has not been established.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- *Patients with known hypersensitivity to phenylbutyrate:* Reactions include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash.

WARNINGS AND PRECAUTIONS

- *Neurotoxicity:* Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels of 500 micrograms/mL or greater. If symptoms of vomiting, nausea, headache, somnolence, or confusion, are present in the absence of high ammonia or other intercurrent illness which explains these symptoms, consider the potential for PAA neurotoxicity which may need reduction in the RAVICTI dosage.
- *Pancreatic Insufficiency or Intestinal Malabsorption:* Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely.

ADVERSE REACTIONS

The most common adverse reactions reported in clinical trials (at least 10% of patients) were:

- *Adult patients:* diarrhea, flatulence, and headache occurred during 4-week treatment (n=45) with RAVICTI; nausea, vomiting, diarrhea, decreased appetite, dizziness, headache, and fatigue occurred during 12-month treatment (n=51) with RAVICTI.
- *Pediatric patients ages 2 to 17 years:* upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, and headache occurred during 12-month treatment (n=26) with RAVICTI.
- *Pediatric patients ages 2 months to less than 2 years:* neutropenia, vomiting, constipation, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash, and papule occurred during 12-month treatment (n=17) with RAVICTI.
- *Pediatric patients less than 2 months of age:* vomiting, rash, gastroesophageal reflux, increased hepatic enzymes, feeding disorder (decreased appetite, hypophagia), anemia, cough, dehydration, metabolic acidosis, thrombocytosis, thrombocytopenia, neutropenia, lymphocytosis, diarrhea, flatulence, constipation, pyrexia, lethargy, and irritability/agitation occurred during 24-month treatment (n=16) with RAVICTI.

DRUG INTERACTIONS

- Corticosteroids, valproic acid, or haloperidol may increase plasma ammonia level. Monitor ammonia levels closely.
- Probenecid may affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA.
- CYP3A4 substrates with narrow therapeutic index (eg, alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure to the concomitant drug.
- Midazolam: Use of RAVICTI decreased exposure of midazolam with concomitant use.

USE IN SPECIFIC POPULATIONS

- *Pregnancy:* RAVICTI should be used with caution in patients who are pregnant or planning to become pregnant. Based on animal data, RAVICTI may cause fetal harm. Report pregnancies to Amgen at 1-866-479-6742.
- *Lactation:* breastfeeding is not recommended during treatment with RAVICTI. There are no data on the presence of RAVICTI in human milk, the effects on the breastfed infant, nor the effects on milk production.

Please see accompanying Full Prescribing Information.



Patient Enrollment Form Guide

The Patient Enrollment Form (PEF) must be completely filled out in order to get your patients started on RAVICTI® (glycerol phenylbutyrate) Oral Liquid and initiate their enrollment in Amgen By Your Side, a patient support program. This guide is designed to help you understand the different fields on the form and how to complete the form accurately for submission.

Three easy steps to initiate the patient enrollment process for RAVICTI® (glycerol phenylbutyrate) Oral Liquid:



Fill out all required fields on pages 1 and 2 as indicated by the asterisks, including the prescriber signature and date within the Prescriber section



Obtain the patient consent ("I Consent" check box), patient signature and date within the Patient Consent and Authorization section at the top of page 2, if possible



Send both the front and back of the patient's insurance card(s) along with all 4 pages of the PEF

Two ways to submit the Patient Enrollment Form:

- Email: UCDABYS@amgen.com
- Fax: 1-877-695-8304

Please see Important Safety Information for RAVICTI Oral Liquid at the end of this guide, and accompanying Full Prescribing Information for RAVICTI.

If you have any questions while completing the form, please contact Amgen By Your Side at 1-855-823-7878.



RAVICTI PATIENT ENROLLMENT FORM

Once complete, submit pages 1-4 by fax 1-877-695-8304 or email UCDBYVS@amgen.com

Initiate the patient enrollment process by completing ALL REQUIRED FIELDS indicated by *.
For patient support and/or assistance obtaining patient signature, call Amgen By Your Side at 1-855-823-7878.

USA-ABYS-80168 11/25

1

1. PATIENT INFORMATION

First name* Last name* Primary language
Address* City* State* ZIP*
Mobile phone* Primary Home phone* Primary
Email* Date of birth* (MM/DD/YYYY) Gender*: Male Female

ALTERNATIVE CONTACT AND/OR CAREGIVER

First name Last name Email
Mobile phone Primary Home phone Primary Relationship to patient

2

2. INSURANCE INFORMATION

Please attach copies of the front and back of patient's medical and prescription insurance cards.

No Insurance

Primary insurance* Secondary insurance
Insurance company phone* Insurance company phone
Policy type*: Commercial Medicaid Medicare Other Policy type: Commercial Medicaid Medicare Other
Policy #* Group #* Policy # Group #
Policyholder name* Policyholder name
Relationship* Policyholder's (MM/DD/YYYY) date of birth* Relationship Policyholder's (MM/DD/YYYY) date of birth*
Prescription card*: Yes No If yes, carrier Phone
Identification # Policy/Group #
Policyholder name Relationship Policyholder's (MM/DD/YYYY) date of birth

3

3. DIAGNOSIS

Ornithine transcarbamylase deficiency/OTC (E72.4) Argininosuccinate lyase deficiency/ASL (E72.22) Argininemia/ARG (E72.21)
 Carbamoyl phosphate synthetase/CPS (E72.29) Citrullinemia/ASSD (E72.23)
 Hyperammonemia-hyperornithinemia-homocitrullinuria syndrome/HHH (E72.4) Disorder of urea cycle metabolism, unspecified (E72.20)
 Other diagnosis, ICD-10 _____ Please visit www.icd10data.com/Convert/270.6 for more information.
Current Nitrogen Scavenger: Sodium phenylbutyrate Sodium benzoate Sodium phenylbutyrate and sodium benzoate
 No nitrogen scavenger

Complete signatures and prescription information on next page

Page 1 of 4

USA-ABYS-80168 11/25

1 Patient Information

Provide the patient's demographic and contact information; only one patient phone number required, mobile OR home

- Required fields are needed to conduct a benefits investigation, contact the patient for any follow-up, and provide support from Amgen By Your Side
- Alternate contact information is optional
- It may help to include a caregiver's contact information

2 Insurance Information

Provide the patient's primary insurance information (required to conduct a benefits investigation)

Include secondary insurance information, if applicable, to improve the accuracy of the benefits investigation

If the patient does not have any insurance check the "Patient is uninsured to my knowledge" box

(Continued)

- ! Please include the front and back of your patient's insurance card(s), if available, along with the completed Patient Enrollment Form
- If not available, or if the patient is uninsured, you may attach the electronic medical record demographics page as an alternative to the image of the cards

3 Diagnosis

Provide the diagnosis code

- If there is no box, select "Other ICD-10 code" and note the primary diagnosis code
- Select the patient's current nitrogen scavenger or that the patient is not taking one

Disclaimer: The information provided on this form is for demonstration purposes only and does not represent any real person.

Please see Important Safety Information for RAVICTI Oral Liquid at the end of this guide, and accompanying Full Prescribing Information for RAVICTI.

4

4. PATIENT CONSENT AND AUTHORIZATION

USA-ABYS-80168 11/25

You must read the Consent to Health Data Processing on page 4 and then select one of the below responses. Select "I consent" to proceed with enrollment. If you select "I do not consent," you will not be able to enroll in Amgen By Your Side.

- I consent to the collection, processing, and disclosure of my Health Data for the purposes set forth on page 4.
 I do not consent to the collection, processing, or disclosure of my Health Data for the purposes set forth on page 4.

By signing below, I am indicating that I have read and understood the Authorization for Use and Disclosure of Protected Health Information (pages 3-4), that I am legally authorized to consent, and that I am providing my consent as the patient or the patient's legal representative for Amgen and its contractors and business partners to use and share the personal information I provide for the purposes described within the Authorization for Use and Disclosure of Protected Health Information.

Patient name* Name of Legal Representative (if applicable)
Signature of patient (or Legal Representative)* Date* (MM/DD/YYYY)

5

5. PRESCRIPTION INFORMATION

Patient first name* Patient last name* Date of Birth* (MM/DD/YYYY)

RAVICTI* (glycerol phenylbutyrate) Oral Liquid, 11 g/mL Allergies*: _____ or No known drug allergies (NKDA)

Patient weight*: _____ lbs OR _____ kg Patient height*: in cm

Dose* Doses per Day* Total Daily Dose* Days' Supply*

Total Quantity* # Refills* Instructions*

State requirements: The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to the prescriber.

6. PRESCRIBER INFORMATION

Preferred Method of Contact Email Phone

First name* Last name* Credentials

NPI #* State license #* State issued* Tax ID* Specialty

Practice/facility name* Office contact name*

Address* City* State* ZIP*

Office contact phone* Fax* Office contact email*

Signature below indicates prescription authorization and prescriber certification.

Prescriber Signature* (sign one line ONLY)

Written or e-signature only, stamps not acceptable.

Dispense as written Date: ___/___/___ Substitutions permitted Date: ___/___/___

For Providers in Texas and Florida ONLY:

For prescriptions in which the brand intends to be dispensed, please handwritten "Brand Medically Necessary" in the box provided:

Prescriber Certification: I certify that the above therapy is medically necessary, that the information provided is accurate to the best of my knowledge and that my patient is being administered RAVICTI in accordance with the labeled use of the product. I represent that my patient has requested and authorized the disclosure of their personal information to Amgen, Inc. and its affiliates and their respective employees or agents collectively "Amgen" for Amgen to administer the Amgen By Your Side program (the "Program"), which provides patient-focused support, including providing logistical and non-medical treatment support for RAVICTI as prescribed, and educating about the insurance process. I further represent that I have explained to the patient, and the patient indicated they understand and have consented to, the following: 1) Amgen will use the patient's name, date of birth, contact information, prescriptions, and other necessary health information to administer the Program; 2) Amgen will then disclose the patient's personal information to the patient's insurer(s) for the same purposes; 3) the patient can withdraw their consent by contacting Amgen at 1-844-469-4297 or visiting www.amgen.com/DataSubjectRights, but if the patient does not agree to, or withdraws consent for, these uses and disclosures, the patient cannot receive these patient support services for this medication which necessarily requires Amgen to process the patient's personal information; and 4) the patient can view more details about Amgen's privacy practice at www.amgen.com/privacy. I authorize Amgen to transmit this prescription on my behalf to the appropriate pharmacy designated by the patient utilizing their benefit plan by any means allowed under applicable law. I further understand and agree that (a) any medication or service provided through the Program as a result of this form is for the named patient only and is not being made in exchange for any express or implied agreement or understanding that I would recommend, prescribe, or use RAVICTI or any other Amgen product or service, for any other person; (b) my decision to prescribe RAVICTI was based solely on my professional determination of medical necessity; and (c) I will not seek reimbursement for any medication or service provided by or through the Program from any government program or third-party insurer. I understand that Amgen may modify or terminate the Program at any time without notice. The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Amgen makes no representation or guarantee concerning coverage or reimbursement for any item or service.

State requirements: I certify that the prescription I am submitting as part of this Patient Enrollment Form complies with my state's prescription requirements (e.g., e-prescribing, state-specific prescription form, fax language). I understand that noncompliance with my state's specific prescription requirements will result in outreach to me to obtain a compliant prescription.

By filing out and signing this form, the enrollment process in Amgen By Your Side has initiated; however, your patient must sign a Patient Authorization to complete enrollment in Amgen By Your Side. Please note that your patient will not benefit from the services and support offered by the Program unless your patient signs a Patient Authorization, consenting to receiving such services. If your patient does not sign the Patient Authorization contained within this form, Amgen will contact the patient to determine whether the patient is interested in signing a separate Patient Authorization.

Page 2 of 4

USA-ABYS-80168 11/25

4 Patient Consent and Authorization

- Patient must sign and date form
- Patient must check "I consent" circle in order to be enrolled in Amgen By Your Side
- If the patient can't sign the form at your office, Amgen By Your Side can follow up to obtain consent

5 Prescription Information

All prescription fields must be fully completed. Incomplete information may result in delays at specialty pharmacies and additional outreach for prescription clarification.

6 Prescriber Information

- Provide the prescriber's name, contact information, NPI, tax ID, and state license numbers, which are required for processing
- Prescriber signature is required for processing the Patient Enrollment Form
- Must be a written or e-signature, stamps are not accepted

Pages 3-4 of the PEF include the patient authorization and consent language. Once the PEF is submitted, you can provide these 2 pages to the patient for their reference.

Please see Important Safety Information for RAVICTI Oral Liquid at the end of this guide, and accompanying Full Prescribing Information for RAVICTI.

Patient Enrollment Form Guide

The Patient Enrollment Form (PEF) must be completely filled out in order to get your patients started on RAVICTI® (glycerol phenylbutyrate) Oral Liquid and initiate their enrollment in Amgen By Your Side, a patient support program. This guide is designed to help you understand the different fields on the form and how to complete the form accurately for submission.

Three easy steps to initiate the patient enrollment process for RAVICTI® (glycerol phenylbutyrate) Oral Liquid:



Fill out all required fields on pages 1 and 2 as indicated by the asterisks, including the prescriber signature and date within the Prescriber section



Obtain the patient consent (“I Consent” check box), patient signature and date within the Patient Consent and Authorization section at the top of page 2, if possible



Send both the front and back of the patient’s insurance card(s) along with all 4 pages of the PEF

Two ways to submit the Patient Enrollment Form:

- Email: UCDABYS@amgen.com
- Fax: 1-877-695-8304

Please see Important Safety Information for RAVICTI Oral Liquid at the end of this guide, and [click here for Full Prescribing Information for RAVICTI](#).

If you have any questions while completing the form, please contact Amgen By Your Side at 1-855-823-7878.

RAVICTI PATIENT ENROLLMENT FORM

Once complete, submit pages 1-4 by fax 1-877-895-8304 or email UCDABYS@amgen.com

Initiate the patient enrollment process by completing ALL REQUIRED FIELDS indicated by *. For patient support and/or assistance obtaining patient signature, call Amgen By Your Side at 1-855-823-7878.

USA-ABYS-80168 11/25



1

1. PATIENT INFORMATION

First name* _____ Last name* _____ Primary language _____
Address* _____ City* _____ State* _____ ZIP* _____
Mobile phone* _____ Primary _____ Home phone* _____ Primary _____
Email* _____ Date of birth* (MM/DD/YYYY) _____ Gender*: Male Female

ALTERNATIVE CONTACT AND/OR CAREGIVER

First name _____ Last name _____ Email _____
Mobile phone _____ Primary _____ Home phone _____ Primary _____ Relationship to patient _____

2

2. INSURANCE INFORMATION Please attach copies of the front and back of patient's medical and prescription insurance cards.

No insurance

Primary insurance* _____ Insurance company phone* _____ Policy type*: <input type="radio"/> Commercial <input type="radio"/> Medicaid <input type="radio"/> Medicare <input type="radio"/> Other Policy #* _____ Group #* _____ Policyholder name* _____ Relationship* _____ Policyholder's (MM/DD/YYYY) date of birth* _____ Prescription card*: <input type="radio"/> Yes <input type="radio"/> No If yes, carrier _____ Phone _____ Identification # _____ Policy/Group # _____ Policyholder name _____ Relationship _____ Policyholder's (MM/DD/YYYY) date of birth _____	Secondary insurance _____ Insurance company phone _____ Policy type: <input type="radio"/> Commercial <input type="radio"/> Medicaid <input type="radio"/> Medicare <input type="radio"/> Other Policy # _____ Group # _____ Policyholder name _____ Relationship _____ Policyholder's (MM/DD/YYYY) date of birth _____
---	--

3

3. DIAGNOSIS

Ornithine transcarbamylase deficiency/OTC (E72.4) Argininosuccinate lyase deficiency/ASL (E72.22) Argininemia/ARG (E72.21)
 Carbamoyl phosphate synthetase/CPS (E72.29) Citrullinemia/ASSD (E72.23)
 Hyperammonemia-hyperornithinemia-homocitrullinuria syndrome/HHH (E72.4) Disorder of urea cycle metabolism, unspecified (E72.20)
 Other diagnosis, ICD-10 _____ Please visit www.icd10data.com/Convert/270.8 for more information.
Current Nitrogen Scavenger: Sodium phenylbutyrate Sodium benzoate Sodium phenylbutyrate and sodium benzoate
 No nitrogen scavenger

Complete signatures and prescription information on next page

Page 1 of 4

USA-ABYS-80168 11/25

1 Patient Information

Provide the patient's demographic and contact information; only one patient phone number required, mobile OR home

- Required fields are needed to conduct a benefits investigation, contact the patient for any follow-up, and provide support from Amgen By Your Side
- Alternate contact information is optional
 - It may help to include a caregiver's contact information

2 Insurance Information

Provide the patient's primary insurance information (required to conduct a benefits investigation)

Include secondary insurance information, if applicable, to improve the accuracy of the benefits investigation

If the patient does not have any insurance check the "Patient is uninsured to my knowledge" box

(Continued)

- ! Please include the front and back of your patient's insurance card(s), if available, along with the completed Patient Enrollment Form
 - If not available, or if the patient is uninsured, you may attach the electronic medical record demographics page as an alternative to the image of the cards

3 Diagnosis

Provide the diagnosis code

- If there is no box, select "Other ICD-10 code" and note the primary diagnosis code
- Select the patient's current nitrogen scavenger or that the patient is not taking one

Disclaimer: The information provided on this form is for demonstration purposes only and does not represent any real person.

Please see Important Safety Information for RAVICTI Oral Liquid at the end of this guide, and click here for Full Prescribing Information for RAVICTI.

4

4. PATIENT CONSENT AND AUTHORIZATION (Required - please see language on pages 3-4)

USA-ABYS-80168 11/25

You must read the Consent to Health Data Processing on page 4 and then select one of the below responses.

Select "I consent" to proceed with enrollment. If you select "I do not consent," you will not be able to enroll in Amgen By Your Side.

- I consent to the collection, processing, and disclosure of my Health Data for the purposes set forth on page 4.
 I do not consent to the collection, processing, or disclosure of my Health Data for the purposes set forth on page 4.

By signing below, I am indicating that I have read and understood the Authorization for Use and Disclosure of Protected Health Information (pages 3-4), that I am legally authorized to consent, and that I am providing my consent as the patient or the patient's legal representative for Amgen and its contractors and business partners to use and share the personal information I provide for the purposes described within the Authorization for Use and Disclosure of Protected Health Information.

Patient name* _____ Name of Legal Representative (if applicable) _____
 Signature of patient (or Legal Representative)* _____ Date* (MM/DD/YYYY) _____

5

5. PRESCRIPTION INFORMATION

Patient first name* _____ Patient last name* _____ Date of Birth* (MM/DD/YYYY) _____

RAVICTI® (glycerol phenylbutyrate) Oral Liquid, 1.1 g/mL Allergies*: _____ or No known drug allergies (NKDA)

Patient weight*: _____ lbs OR _____ kg Patient height*: _____ in cm

Dose* _____ Doses per Day* _____ Total Daily Dose* _____ Days' Supply* _____

Total Quantity* _____ # Refills* _____ Instructions* _____

State requirements: The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to the prescriber.

6. PRESCRIBER INFORMATION

Preferred Method of Contact Email Phone

First name* _____ Last name* _____ Credentials _____

NPI #* _____ State license #* _____ State issued* _____ Tax ID* _____ Specialty _____

Practice/Facility name* _____ Office contact name* _____

Address* _____ City* _____ State* _____ ZIP* _____

Office contact phone* _____ Fax* _____ Office contact email* _____

Signature below indicates prescription authorization and prescriber certification.

Prescriber Signature* (sign one line ONLY)

Written or e-signature only; stamps not acceptable.

Dispense as written _____ Date: ____/____/____ Substitutions permitted _____ Date: ____/____/____

For Providers in Texas & Florida ONLY:
 For prescriptions in which the brand intends to be dispensed,
 please handwrite "Brand Medically Necessary" in the box provided:

Prescriber Certification: I certify that the above therapy is medically necessary, that the information provided is accurate to the best of my knowledge and that my patient is being administered RAVICTI in accordance with the labeled use of the product. I represent that my patient has requested and authorized the disclosure of their personal information to Amgen, Inc. and its affiliates and their respective employees or agents (collectively, "Amgen") for Amgen to administer the Amgen By Your Side program (the "Program"), which provides patient-focused support, including providing logistical and non-medical treatment support for RAVICTI as prescribed, and educating about the insurance process. Further, I represent that I have explained to the patient, and the patient indicated they understand and have consented to, the following: 1) Amgen will use the patient's name, date of birth, contact information, prescriptions, and other necessary health information to administer the Program; 2) Amgen will then disclose the patient's personal information to the patient's insurer(s) for the same purposes; 3) the patient can withdraw their consent by contacting Amgen at 1-844-469-4297 or visiting www.amgen.com/DataSubjectRights, but if the patient does not agree to, or withdraws consent for, these uses and disclosures, the patient cannot receive these patient support services for this medication which necessarily requires Amgen to process the patient's personal information; and 4) the patient can view more details about Amgen's privacy practices at www.amgen.com/privacy. I authorize Amgen to transmit this prescription on my behalf to the appropriate pharmacy designated by the patient utilizing their benefit plan by any means allowed under applicable law. I further understand and agree that (a) any medication or service provided through the Program as a result of this form is for the named patient only and is not being made in exchange for any express or implied agreement or understanding that I would recommend, prescribe, or use RAVICTI or any other Amgen product or service, for any other person; (b) my decision to prescribe RAVICTI was based solely on my professional determination of medical necessity; and (c) I will not seek reimbursement for any medication or service provided by or through the Program from any government program or third-party insurer. I understand that Amgen may modify or terminate the Program at any time without notice. The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Amgen makes no representation or guarantee concerning coverage or reimbursement for any item or service.

State requirements: I certify that the prescription I am submitting as part of this Patient Enrollment Form complies with my state's prescription requirements (e.g., e-prescribing, state-specific prescription form, fax language). I understand that noncompliance with my state's specific prescription requirements will result in outreach to me to obtain a compliant prescription.

By filling out and signing this form, the enrollment process in Amgen By Your Side has initiated; however, your patient must sign a Patient Authorization to complete enrollment in Amgen By Your Side. Please note that your patient will not benefit from the services and support offered by the Program unless your patient signs a Patient Authorization, consenting to receiving such services. If your patient does not sign the Patient Authorization contained within this form, Amgen will contact the patient to determine whether the patient is interested in signing a separate Patient Authorization.

Page 2 of 4

USA-ABYS-80168 11/25

4 Patient Consent and Authorization

- Patient must sign and date form
- Patient must check "I consent" circle in order to be enrolled in Amgen By Your Side
- If the patient can't sign the form at your office, Amgen By Your Side can follow up to obtain consent

5 Prescription Information

All prescription fields must be fully completed. Incomplete information may result in delays at specialty pharmacies and additional outreach for prescription clarification.

6 Prescriber Information

- Provide the prescriber's name, contact information, NPI, tax ID, and state license numbers, which are required for processing
- Prescriber signature is required for processing the Patient Enrollment Form
 - Must be a written or e-signature, stamps are not accepted

Pages 3-4 of the PEF include the patient authorization and consent language. Once the PEF is submitted, you can provide these 2 pages to the patient for their reference.

Please see Important Safety Information for RAVICTI Oral Liquid at the end of this guide, and click here for Full Prescribing Information for RAVICTI.

Connecting Patients with their Amgen By Your Side PAL

The Patient Access Liaison (PAL) is a dedicated support partner who helps investigate, explain, and educate on the steps in your patient's treatment experience. They are your patient's point of contact and champion while your patient is accomplishing their treatment goals.

- Make sure the patient is aware their PAL will be calling them in the next few days to provide information on next steps and getting started on RAVICTI
- Have the patient save their PAL's contact in their phone
 - **It is important that a patient answers the PAL's call**

PAL Name: _____

Phone Number: _____

Please ensure that all four pages of the enrollment forms are submitted by fax to 1-877-695-8304 or emailed to UCDABYS@amgen.com. Incomplete forms may delay enrollment.

INDICATION and IMPORTANT SAFETY INFORMATION FOR RAVICTI (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID

INDICATION

RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).

LIMITATIONS OF USE

- RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels.
- The safety and efficacy of RAVICTI for the treatment of *N*-acetylglutamate synthase (NAGS) deficiency has not been established.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- *Patients with known hypersensitivity to phenylbutyrate:* Reactions include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash.

WARNINGS AND PRECAUTIONS

- *Neurotoxicity:* Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels of 500 micrograms/mL or greater. If symptoms of vomiting, nausea, headache, somnolence, or confusion, are present in the absence of high ammonia or other intercurrent illness which explains these symptoms, consider the potential for PAA neurotoxicity which may need reduction in the RAVICTI dosage.
- *Pancreatic Insufficiency or Intestinal Malabsorption:* Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely.

ADVERSE REACTIONS

The most common adverse reactions reported in clinical trials (at least 10% of patients) were:

- *Adult patients:* diarrhea, flatulence, and headache occurred during 4-week treatment (n=45) with RAVICTI; nausea, vomiting, diarrhea, decreased appetite, dizziness, headache, and fatigue occurred during 12-month treatment (n=51) with RAVICTI.
- *Pediatric patients ages 2 to 17 years:* upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, and headache occurred during 12-month treatment (n=26) with RAVICTI.
- *Pediatric patients ages 2 months to less than 2 years:* neutropenia, vomiting, constipation, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash, and papule occurred during 12-month treatment (n=17) with RAVICTI.
- *Pediatric patients less than 2 months of age:* vomiting, rash, gastroesophageal reflux, increased hepatic enzymes, feeding disorder (decreased appetite, hypophagia), anemia, cough, dehydration, metabolic acidosis, thrombocytosis, thrombocytopenia, neutropenia, lymphocytosis, diarrhea, flatulence, constipation, pyrexia, lethargy, and irritability/agitation occurred during 24-month treatment (n=16) with RAVICTI.

DRUG INTERACTIONS

- Corticosteroids, valproic acid, or haloperidol may increase plasma ammonia level. Monitor ammonia levels closely.
- Probenecid may affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA.
- CYP3A4 substrates with narrow therapeutic index (eg, alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure to the concomitant drug.
- Midazolam: Use of RAVICTI decreased exposure of midazolam with concomitant use.

USE IN SPECIFIC POPULATIONS

- *Pregnancy:* RAVICTI should be used with caution in patients who are pregnant or planning to become pregnant. Based on animal data, RAVICTI may cause fetal harm. Report pregnancies to Amgen at 1-866-479-6742.
- *Lactation:* breastfeeding is not recommended during treatment with RAVICTI. There are no data on the presence of RAVICTI in human milk, the effects on the breastfed infant, nor the effects on milk production.

Please see [Full Prescribing Information](#).

